To compare the benefit and gastrointestinal risk of low-dose aspirin for the secondary prevention of thromboembolic events.
Data were extracted on the inclusion and exclusion criteria, health status on entry, and outcomes using specially developed forms. The data were then transferred to a database and checked against hard copy entries. To facilitate comparison across studies with differing end points, the summary measure 'vascular events' was used. This was defined as MI, stroke or other vascular event (including vascular death). The relative risks (RRs), absolute risk reductions (ARRs) and 95% confidence interval (CIs) were estimated for each outcome variable in each study.
Methods of synthesis
How were the studies combined?
The outcome data were reported differently across the studies. Thus, the results for categories were only pooled if they were reported in the same way. A Peto fixed-effect model was not used for statistical pooling because of differences in the length of follow-up across the studies. Therefore, the RR for each outcome was calculated assuming a constant follow-up time. The pooled RR and the 95% CI were calculated using all studies with reported outcomes. The ARRs were not aggregated because of differences in the follow-up periods across the studies, and were therefore grouped narratively. The numbers-needed-to-treat for GI bleeding events and all-cause mortality were calculated using the pooled risk ratio and the pooled placebo event rates.
How were differences between studies investigated?
Homogeneity of risk across all studies was calculated using the method described by Breslow and Day (see Other Publications of Related Interest).
Results of the review
Six randomised controlled trials (n=6,300) were included in the review.
For all-cause mortality, the RRs for each of the individual studies ranged from 0.5 (95% CI: 0.2, 1.1, p=0.08) to 1.0 (95% CI: 0.3, 3.0, p>0.99), suggesting that the numbers were too small in the individual studies to determine an impact.
The results of the homogeneity test (p=0.7) indicated that the results were homogeneous across the studies.
The pooled RR was 0.82 (95% CI: 0.7, 0.99. p=0.03). The data suggested that aspirin reduces the risk of death by approximately 20% in the studied population. The ARRs ranged from 2.0% (plus or minus 3.1%) at the 12-month follow-up, to 8.7% (plus or minus 6.3%) at the 20-month follow-up. Across all outcomes, the ARRs ranged from 0.9% (plus or minus 3.7%) at the 52-month follow-up, to 18.6% (plus or minus 7.7%) at the 3-month follow-up.
The pooled RR was 0.7 (95% CI: 0.6, 0.8) for vascular events and 0.7 (95% CI: 0.6, 0.8) for MI. Significant heterogeneity was found in both of these results (p<0.001).
Five of the 6 studies reported GI bleeding, which was a rare find: only 58 cases were reported, approximately half of which were severe enough to require withdrawal. There were no reported deaths related to GI bleeding, and GI bleeding led to almost no permanent morbidity. Only one study demonstrated a statistically-significant increased risk of GI bleeding as a result of aspirin intake. The analysis of GI bleeding across all studies suggested a pooled risk ratio of 2.5% (95% CI: 1.4, 4.7, p=0.001). No significant heterogeneity was found (P=0.5).
Only 2 of the 6 included studies reported cases of haemorrhagic stroke; the results were therefore not conclusive, although the pooled RR from the 2 homogeneous (P>0.99) studies was 0.8 (95% CI: 0.7, 1.0). Based on the numberneeded-to-treat with aspirin to either prevent one death or cause one GI bleeding event, it was determined that 1.5 deaths could be prevented for every nonfatal GI bleeding attributed to the use of aspirin.
